| HOME >> MEDICINE >> TECHNOLOGY |
$ (37,938)$ (102,519)Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Depreciation and amortization
16,55114,881Stock-based compensation
17,39910,326Other non-cash transactions
198(657)Impairment of long-lived assets
12,576-Changes in operating assets and liabilities:Accounts receivable
(20,301)6,034Inventory
(795)2,848Other assets
577(200)Accounts payable
4,274(8,046)Accrued compensation
(800)(1,518)Accrued expenses
1,683(4,191)Accrued clinical trial expenses
(2,023)(3,455)Deferred revenue
(47,025)126,795Other liabilities
(247)(559)Net cash (used in) provided by operating activities
(55,871)39,739Cash flows from investing activities:Purchases of investments
(443,122)(451,918)Sales of investments
15,47917,318Maturities of investments
475,813310,707Purchases of property and equipment
(31,457)(16,390)Advance payments for property and equipment
-(4,312)Transaction costs from Novartis pulmonary asset sale
-(4,440)Net cash provided by (used in) investing activities
16,713(149,035)Cash flows from financing activities:Payments of loan and capital lease obligations
(1,356)(1,285)Proceeds from issuances of common stock
8,8914,820Net cash provided by financing activities
7,5353,535Effect of exchange rates on cash and cash equivalents
(219)(226)Net decrease in cash and cash equivalents
$ (31,842)$ (105,987)Cash and cash equivalents at beginning of period
49,597155,584Cash and cash equivalents at end of period
$ 17,755$
49,597
'/>"/>
| SOURCE Nektar Therapeutics Copyright©2010 PR Newswire. All rights reserved |